5 years ago
Turbine Raises €5.7 Million in Pre-Series A Funding Led by Accel
Turbine, a London and Budapest-based biotechnology company, has closed a €5.7 million (USD 6.85 million) pre-Series A funding round led by Accel, with participation from XTX Ventures, Boston Millenia Partners, Delin Ventures, Atlantic Labs, and o2h Ventures
Turbine is developing a simulation-based, scalable drug discovery platform called the Simulated Cell™, which unlocks novel therapies for high unmet oncology needs
The technology has been validated in numerous collaborations with pharmaceutical companies, including Bayer
The platform offers significant benefits over industry standard screening methods by providing granular insight into the molecular mechanism of target-disease interactions.
ProblemHealthcare
"tackle the highest unmet need in oncology diseases"
Solution
"developing a simulation-based, scalable drug discovery platform, the Simulated Cell™, which unlocks novel therapies"